An interventional study of TAVR with DurAVR® THV and TAVR with SAPIEN THV series or the Evolut THV series in Severe Aortic Stenosis and Valve-in-valve Procedures, sponsored by Anteris Technologies Ltd.. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Anteris Technologies Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 4th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2025, is one of 28 with no phase, reaches primary completion later than 21 of the 27 other live ones, and was the 71st registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark, Sweden
Ages 18+
Ole De Backer · Sites in Denmark, Belgium, Finland and 3 more countries
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Sahajanand Medical Technologies Limited · Sites in Denmark
Ages 18–99
Novartis Pharmaceuticals · Sites in Denmark, United States, Austria and 12 more countries
Ages 50–80
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 7
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,650 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 214 across the 40 interventional studies, 200 across the 33 observational. Of the 37 that completed or were terminated, 10 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 73 have an industry lead sponsor. The 10 most frequent:
Anteris Technologies Ltd. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Anteris Technologies Ltd. has 6 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Aortic Valve Stenosis with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05758662St. Antonius HospitalThe Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI) | 2027-06 |
| NCT06638268Rigshospitalet, DenmarkTranscatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock | 2027-07-01 |
| NCT06470022Christian Juhl TerkelsenComparison of Evolut FX Versus Sapien 3 Ultra Resilia. | 2027-07-14 |
Add all 6 to your calendar (.ics) → With an account.
Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, randomized, controlled, multicenter, international study.
Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'All Comers Randomized Cohort'. Subjects will be randomized 1:1 to receive either the DurAVR® THV System or any commercially available and approved Transcatheter Heart Valve (THV) from the SAPIEN series or the Evolut series and followed for 10 years.
After completion of the All Comers Randomized Cohort, up to 446 additional low-risk subjects will be randomized 1:1 in the 'Low Risk Randomized Continued Access Cohort'.
Up to 150 subjects with a failed surgical bioprosthesis who are deemed high surgical risk and who need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry (ViV Registry Cohort) and followed for 5 years. Subjects in the ViV Registry Cohort will only receive the DurAVR® THV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Native Aortic Stenosis Cohorts:
ViV Registry Cohort:
Exclusion Criteria:
Native Aortic Stenosis Cohorts:
ViV Registry Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DurAVR® THV implantation
Device: TAVR with DurAVR® THV
SAPIEN THV series or the Evolut THV series implantation
Device: TAVR with SAPIEN THV series or the Evolut THV series
Transcatheter aortic valve replacement (TAVR)
Transcatheter aortic valve replacement (TAVR)
Composite of all-cause mortality, all stroke and cardiovascular hospitalization
Composite of all-cause mortality, all stroke and cardiovascular hospitalization
Time frame: 1 Year
All-cause mortality
Mortality from any cause will by collected by tracking patient's living status via medical record
Time frame: 30 Days
Disabling stroke according to VARC-3 Guidelines
The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.
Time frame: 30 Days
Life-threatening bleeding according to VARC-3 Guidelines
The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.
Time frame: 30 Days
Major vascular complication according to VARC-3 Guidelines
The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.
Time frame: 30 Days
Acute Kidney Injury (Stage III or IV) according to VARC-3 Guidelines
The precise categorization is outlined in the Valve Academic Research Consortium-3 (VARC-3) criteria.
Time frame: 30 Days
Mean Aortic Valve (AV) Gradient
Mean Aortic Valve pressure gradient in mm Hg
Time frame: 30 Days and 1 Year
Valve-related dysfunction requiring a repeat procedure
New intervention due to the valve not properly functioning
Time frame: 30 Days and 1 Year
Doppler Velocity Index (DVI)
Doppler Velocity Index
Time frame: 30 Days and 1 Year
Non-Structural Valve Dysfunction
Any abnormality, not intrinsic to the prosthetic valve, resulting in the valve not properly functioning
Time frame: 30 Days and 1 Year
Prosthesis-Patient Mismatch
Calculated in percentage
Time frame: 30 Days and 1 Year
Aortic Regurgitation (AR)
AR grading: None/Trace, Mild, Moderate, Severe
Time frame: 30 Days and 1 Year
New Permanent Pacemaker Implantation (PPI)
New pacemaker implantation in subjects experiencing conduction abnormalities
Time frame: 30 Days and 1 Year
New York Heart Association (NYHA) Class
NYHA Class graded as I, II, III or IV
Time frame: 30 Days and 1 Year
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 26 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anteris Technologies Ltd.